Solutions
Online Inquiry

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Inquiry

Long Linear Peptide Development Platform

Long-chain peptides are comparable in size to the mean protein domain and can be used to treat human diseases. Our company has rich experience and mature technology in the synthesis of long linear peptides and has helped global customers complete several long linear peptide development services. At the same time, we have spared no effort to build and improve the long linear peptide development platform to improve the efficiency of customers in rare disease research.

Overview of Long Linear Peptides

Linear peptides generally include short linear peptides and long linear peptides. Compared with short linear peptides, the peptide chain of long linear peptides is significantly extended, usually containing 100-200 residues, so the synthesis of long linear peptides is more complex. Long linear peptides can participate in a variety of physiological and pathological processes and regulate a variety of cellular functions. Therefore, it is crucial to develop appropriate reaction conditions and methods to synthesize long linear peptides.

2-1-4-2 Long Linear Peptide Development Platform-1Fig.1 Recent advances in peptide-based drug discovery. (Sharma, K., et al., 2022)

SPPS for Long Linear Peptides

Solid phase peptide synthesis (SPPS) is a common method for long linear peptide synthesis. SPPS is carried out on a solid support in a stepwise manner from the C-terminus to the N-terminus to synthesize long-chain peptides. Nα-protected amino acids can reduce side reactions during the synthesis process. SPPS is widely used due to its characteristics of automation, low cost, high scalability, and high efficiency.

Our Services

With rich experience, our company's long linear peptide development platform can provide you with customized peptide development and peptide analysis, including PK studies and safety evaluation. Our peptide purification solutions provide long-chain peptides of varying purity according to customer requirements.

Short Linear Peptide Synthesis

Provides rich technical capabilities, such as liquid phase peptide synthesis (LPPS) to support the synthesis of short linear peptides.

Long Linear Peptide Synthesis

Our company has the ability and experience to synthesize 100-200 amino acid peptides, and is supported by technology platforms including solid phase peptide synthesis (SPPS).

Peptide Isolation and Purification

Provides HPLC and fully automated ion exchange resin systems for the isolation and purification of peptides, as well as peptide analysis using electrospray Ionization (ESI) mass spectrometry.

Impurity Profiling and Characterization

Our company's analytical platform features advanced chromatography, mass spectrometry and chromatographic equipment and technologies to support the profiling and characterization of impurities.

Why Choose Us?

2-1-4-2 Long Linear Peptide Development Platform-2
  • Fast and cost-efficient workflow
  • Timely project reporting and after-sales service
  • One-stop platform with an experienced technical team
  • Stringent quality control and testing
  • Expertise and experience in the industry
  • Careful design and transparent operation process

Project Workflow

2-1-4-2 Long Linear Peptide Development Platform-3

As an integrated CRO, our company provides clients with a cost-effective and convenient solution. Our long linear peptide development service is a simplified workflow by a group of specially trained and experienced scientists. We have the capabilities and resources to provide professional communication and problem-solving support to ensure that we can quickly respond to the changing needs of your rare disease therapy research projects. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.

Reference

  • Sharma, K., et al. "Peptide-based drug discovery: Current status and recent advances." Drug Discovery Today (2022): 103464.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Related Disease Solutions

Copyright © Protheragen. All rights reserves.